- Description
- Table of Contents
- Request Sample
The Idiopathic Pulmonary Fibrosis market is expected to reach $5,733.24 million by 2026 growing at a CAGR of 13.5% from 2018 to 2026. Idiopathic pulmonary fibrosis is a type of interstitial lung disease in which scarring and thickening of the lung tissue occur due to unknown causes. In turn, this fibrosis reduces the ability of alveoli to transport oxygen from the lungs to the bloodstream and results in symptoms such as dyspnea, chronic dry cough, fatigue, and weight loss. Factors such as the rise in geriatric population, a surge in cigarette smoking population and an increase in a number of patients suffering from idiopathic pulmonary fibrosis are fuelling the market growth. However, unavailability of proper treatment options is restricting the market growth. Based on the route of administration, the parenteral route segment is to be the most preferred route of drug administration during the forecast period. Drugs administered by the parenteral route bypass the first-pass metabolism and enter the bloodstream directly. This helps in the fast delivery of drugs or nutrients into the body. The key vendors mentioned are Biogen, Boehringer Ingelheim, MediciNova, Inc., Afferent Pharmaceuticals, Baxter, Bristol-Myers Squibb, F. Hoffmann-La Roche, Promedior, Prometheus Laboratories, Amgen, FibroGen, Merck, Prometic Life Sciences, Galapagos, Cipla Inc., Asahi Kasei Corporation, and Sanofi SA. Types Covered: • Antifibrotic Agents • Systemic Corticosteroids • Immunosuppressant Drugs • Tyrosine Kinase Inhibitors Drugs Types Covered: • Nintedanib • Pirfenidone Route of Administrations Covered • Parenteral • Oral Applications Covered: • Malaria • Arrhythmias • Other Applications End Users Covered • Clinics • Academic and Research Organizations • Hospitals • Ambulatory Surgical Centers • Other End Users Regions Covered: • North America • Europe • Asia Pacific • South America • Middle East & Africa Key Questions Answered in this Report: • How this market evolved since the year 2016 • Market size estimations, forecasts and CAGR for all the segments presented in the scope • Key Market Developments and financials of the key players • Opportunity Analysis for the new entrants • SWOT Analysis of the key players • Fastest growing markets analysed during the forecast period
1 Market Synopsis
2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources
3 Market Dynamics
3.1 Drivers
3.2 Restraints
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Idiopathic Pulmonary Fibrosis Market, By Type
5.1 Introduction
5.2 Antifibrotic Agents
5.3 Systemic Corticosteroids
5.4 Immunosuppressant Drugs
5.5 Tyrosine Kinase Inhibitors
6 Global Idiopathic Pulmonary Fibrosis Market, By Drug Type
6.1 Introduction
6.2 Nintedanib
6.3 Pirfenidone
7 Global Idiopathic Pulmonary Fibrosis Market, By Route of Administration
7.1 Introduction
7.2 Parenteral
7.3 Oral
8 Global Idiopathic Pulmonary Fibrosis Market, By Application
8.1 Introduction
8.2 Malaria
8.3 Arrhythmias
8.4 Other Applications
9 Global Idiopathic Pulmonary Fibrosis Market, By End User
9.1 Introduction
9.2 Clinics
9.3 Academic and Research Organizations
9.4 Hospitals
9.5 Ambulatory Surgical Centers
9.6 Other End Users
10 Global Idiopathic Pulmonary Fibrosis Market, By Geography
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia Pacific
10.5 South America
10.6 Middle East & Africa
11 Strategic Benchmarking
12 Vendors Landscape
12.1 Biogen
12.2 Boehringer Ingelheim
12.3 MediciNova, Inc.
12.4 Afferent Pharmaceuticals
12.5 Baxter
12.6 Bristol-Myers Squibb
12.7 F. Hoffmann-La Roche
12.8 Promedior
12.9 Prometheus Laboratories
12.10 Amgen
12.11 FibroGen
12.12 Merck
12.13 Prometic Life Sciences
12.14 Galapagos
12.15 Cipla Inc.
12.16 Asahi Kasei Corporation
12.17 Sanofi SA
List of Data Tables
Table 1 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Region (2016-2026) ($MN)
Table 2 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Type (2016-2026) ($MN)
Table 3 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Antifibrotic Agents (2016-2026) ($MN)
Table 4 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Systemic Corticosteroids (2016-2026) ($MN)
Table 5 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Immunosuppressant Drugs (2016-2026) ($MN)
Table 6 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Tyrosine Kinase Inhibitors (2016-2026) ($MN)
Table 7 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Drug Type (2016-2026) ($MN)
Table 8 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Nintedanib (2016-2026) ($MN)
Table 9 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Pirfenidone (2016-2026) ($MN)
Table 10 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Route of Administration (2016-2026) ($MN)
Table 11 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Parenteral (2016-2026) ($MN)
Table 12 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Oral (2016-2026) ($MN)
Table 13 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Application (2016-2026) ($MN)
Table 14 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Malaria (2016-2026) ($MN)
Table 15 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Arrhythmias (2016-2026) ($MN)
Table 16 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Other Applications (2016-2026) ($MN)
Table 17 Global Idiopathic Pulmonary Fibrosis Market Outlook, By End User (2016-2026) ($MN)
Table 18 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Clinics (2016-2026) ($MN)
Table 19 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Academic and Research Organizations (2016-2026) ($MN)
Table 20 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Hospitals (2016-2026) ($MN)
Table 21 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Ambulatory Surgical Centers (2016-2026) ($MN)
Table 22 Global Idiopathic Pulmonary Fibrosis Market Outlook, By Other End Users (2016-2026) ($MN)
Table 23 North America Idiopathic Pulmonary Fibrosis Market Outlook, By Type (2016-2026) ($MN)
Table 24 North America Idiopathic Pulmonary Fibrosis Market Outlook, By Drug Type (2016-2026) ($MN)
Table 25 North America Idiopathic Pulmonary Fibrosis Market Outlook, By Route of Administration (2016-2026) ($MN)
Table 26 North America Idiopathic Pulmonary Fibrosis Market Outlook, By Application (2016-2026) ($MN)
Table 27 North America Idiopathic Pulmonary Fibrosis Market Outlook, By End User (2016-2026) ($MN)
Table 28 Europe Idiopathic Pulmonary Fibrosis Market Outlook, By Type (2016-2026) ($MN)
Table 29 Europe Idiopathic Pulmonary Fibrosis Market Outlook, By Drug Type (2016-2026) ($MN)
Table 30 Europe Idiopathic Pulmonary Fibrosis Market Outlook, By Route of Administration (2016-2026) ($MN)
Table 31 Europe Idiopathic Pulmonary Fibrosis Market Outlook, By Application (2016-2026) ($MN)
Table 32 Europe Idiopathic Pulmonary Fibrosis Market Outlook, By End User (2016-2026) ($MN)
Table 33 Asia Pacific Idiopathic Pulmonary Fibrosis Market Outlook, By Type (2016-2026) ($MN)
Table 34 Asia Pacific Idiopathic Pulmonary Fibrosis Market Outlook, By Drug Type (2016-2026) ($MN)
Table 35 Asia Pacific Idiopathic Pulmonary Fibrosis Market Outlook, By Route of Administration (2016-2026) ($MN)
Table 36 Asia Pacific Idiopathic Pulmonary Fibrosis Market Outlook, By Application (2016-2026) ($MN)
Table 37 Asia Pacific Idiopathic Pulmonary Fibrosis Market Outlook, By End User (2016-2026) ($MN)
Table 38 South America Idiopathic Pulmonary Fibrosis Market Outlook, By Type (2016-2026) ($MN)
Table 39 South America Idiopathic Pulmonary Fibrosis Market Outlook, By Drug Type (2016-2026) ($MN)
Table 40 South America Idiopathic Pulmonary Fibrosis Market Outlook, By Route of Administration (2016-2026) ($MN)
Table 41 South America Idiopathic Pulmonary Fibrosis Market Outlook, By Application (2016-2026) ($MN)
Table 42 South America Idiopathic Pulmonary Fibrosis Market Outlook, By End User (2016-2026) ($MN)
Table 43 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Outlook, By Type (2016-2026) ($MN)
Table 44 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Outlook, By Drug Type (2016-2026) ($MN)
Table 45 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Outlook, By Route of Administration (2016-2026) ($MN)
Table 46 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Outlook, By Application (2016-2026) ($MN)
Table 47 Middle East & Africa Idiopathic Pulmonary Fibrosis Market Outlook, By End User (2016-2026) ($MN)